Literature DB >> 18830251

Peripheral arterial disease and isolated systolic hypertension: the ATTEST study.

M E Safar1, P Priollet, F Luizy, J-J Mourad, P Cacoub, H Levesque, J Benelbaz, P Michon, M-A Herrmann, J Blacher.   

Abstract

Hypertension is a risk factor for cardiovascular (CV) diseases, either coronary artery disease (CAD), peripheral artery disease (PAD) or cerebrovascular disease (CVD). The relationships between those different localizations of CV disease and the haemodynamic features of hypertension have been poorly evaluated in the past. In the ATTEST study, a geographically representative panel of 3020 general practitioners recruited 8316 consecutive patients with CV diseases (PAD, CAD or CVD, alone or in association). Blood pressure, which was not an inclusion criterion, was then measured and related to the different forms of CV diseases. Blood pressure classification involved 20% normotensive subjects, 24% subjects with controlled hypertension, 42% subjects with isolated systolic hypertension and 14% subjects with systolic-diastolic hypertension, all hypertensives with or without antihypertensive therapy. From multiple regression analysis, it appeared that subjects with systolic hypertension were characterized by the presence of PAD, with little or no presence of CAD and/or CVD. Subjects with systolic-diastolic hypertension were characterized by the presence of CAD and/or CVD, but without PAD. Although the former was only influenced by age, dyslipidaemia and diabetes mellitus influenced the latter. This study confirms the high prevalence of hypertension (80%) in a large population of patients with CV diseases selected in primary care. Analysis of different features of hypertension revealed that isolated systolic hypertension was the most prevalent form of hypertension in this treated population. Finally, one of the predominant goals of secondary prevention in subjects with PAD should be the treatment of isolated systolic hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830251     DOI: 10.1038/jhh.2008.121

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

Review 1.  Arterial aging--hemodynamic changes and therapeutic options.

Authors:  Michel E Safar
Journal:  Nat Rev Cardiol       Date:  2010-08       Impact factor: 32.419

2.  Prevalence of isolated systolic hypertension (ISH) in Slovene hypertensive patients: insights from the "Quality of Healthcare in Slovenia" project.

Authors:  Marjetka Pal; Polonca Ferk; Brane Leskošek; Ivan Krajnc; Marjan Pajntar
Journal:  Wien Klin Wochenschr       Date:  2015-03-19       Impact factor: 1.704

3.  [Clinical characteristics and risk factors of lower extremity arterial disease in patients with diabetic foot ulcer].

Authors:  A He; X Ding; J Huang; X Luo; J Meng; Y Cao; F Gao; M Zou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

4.  SEPP1 gene variants and abdominal aortic aneurysm: gene association in relation to metabolic risk factors and peripheral arterial disease coexistence.

Authors:  Ewa Strauss; Grzegorz Oszkinis; Ryszard Staniszewski
Journal:  Sci Rep       Date:  2014-11-14       Impact factor: 4.379

5.  Cross-Sectional Assessment of Achievement of Therapeutic Goals in a Canadian Multidisciplinary Clinic for Patients With Advanced Chronic Kidney Disease.

Authors:  Félix Rinfret; France Lambert; Joseph Tchetagni Youmbissi; Jean-François Arcand; Richard Turcot; Maral Alimardani Bessette; Solange Bourque; Vincent Moreau; Karine Tousignant; Diane Deschênes; Lyne Cloutier
Journal:  Can J Kidney Health Dis       Date:  2018-05-13

Review 6.  β-blockade: benefits beyond blood pressure reduction?

Authors:  John R Cockcroft; Michala E Pedersen
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-11       Impact factor: 3.738

Review 7.  Bench-to-Bedside in Vascular Medicine: Optimizing the Translational Pipeline for Patients With Peripheral Artery Disease.

Authors:  Tom Alsaigh; Belinda A Di Bartolo; Jocelyne Mulangala; Gemma A Figtree; Nicholas J Leeper
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.